본문으로 건너뛰기
← 뒤로

[Body dysmorphic disorder (BDD)].

Presse medicale (Paris, France : 1983) 2012 Vol.41(1) p. e22-35

Tignol J, Martin-Guehl C, Aouizerzate B

📝 환자 설명용 한 줄

【연구 목적】 1987년 DSM-III-R에서 완전한 장애로 인정된 이후 신체형 장애(BDD)에 대한 지식이 증가하고 미용 시술 수요가 늘어난 배경 하에, 프랑스어권 의료진을 대상으로 BDD의 임상적 특징과 치료 현황을 체계적으로 고찰하고자 하였다.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Tignol J, Martin-Guehl C, Aouizerzate B (2012). [Body dysmorphic disorder (BDD)].. Presse medicale (Paris, France : 1983), 41(1), e22-35. https://doi.org/10.1016/j.lpm.2011.05.021
MLA Tignol J, et al.. "[Body dysmorphic disorder (BDD)].." Presse medicale (Paris, France : 1983), vol. 41, no. 1, 2012, pp. e22-35.
PMID 21831574

Abstract

[OBJECTIVE] Body Dysmorphic Disorder (BDD) has replaced the old and ill-defined concept of dysmorphophobia since its introduction as a full-blown disorder in DSM-III-R in 1987. Since then, the body of knowledge on BDD has considerably increased. At the same time, cosmetic medicine and surgical procedures, for which the indications and outcomes of BDD should be taken into account, have become common. Hence, we decided to undertake a review of the literature on BDD aimed at French speaking practitioners.

[METHOD] We searched Medline for the literature on BDD and dysmorphophobia in English and in French and made a critical examination of findings resulting from those studies where the methodology was sound.

[RESULTS] BDD is frequent in the general population with a point prevalence between 1.7 and 2.4% and often severe. Delusive and non-delusive forms of BDD likely belong to the same entity and both respond to the same treatment. Serotonin reuptake inhibitors and cognitive behavioral therapies have demonstrated their efficacy in randomized controlled studies. Esthetic, medical and surgical treatments, which are very often sought after by BDD patients, have been shown to be ineffective and potentially harmful.

[DISCUSSION] Our review confirms the progress in knowledge on BDD. The most interesting results concern clinical characteristics, epidemiology in the general population, and treatment. The prevalence of BDD in the general population should prompt every practitioner to take this disorder into account when faced with the increasing demand for medical and surgical cosmetic procedures. Nevertheless, further research is needed, particularly on the demand of non psychiatric treatments by BDD patients and the way medical or surgical specialists manage it.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
약물 BDD → Body dysmorphic disorder C0005887
Body Dysmorphic Disorders
scispacy 1
약물 Serotonin C0036751
serotonin
scispacy 1
약물 [OBJECTIVE] Body scispacy 1
약물 [RESULTS] BDD scispacy 1
질환 dysmorphic disorder C0005887
Body Dysmorphic Disorders
scispacy 1
질환 BDD → Body dysmorphic disorder C0005887
Body Dysmorphic Disorders
scispacy 1
질환 DSM-III-R C0220951
dsm-iii-r
scispacy 1
질환 dysmorphophobia C0005887
Body Dysmorphic Disorders
scispacy 1
질환 psychiatric C0033873
Psychiatry Specialty
scispacy 1
기타 Serotonin reuptake scispacy 1

MeSH Terms

Body Dysmorphic Disorders; Body Image; Cognitive Behavioral Therapy; Comorbidity; Diagnosis, Differential; Disease Progression; Humans; Prevalence; Social Environment; Somatoform Disorders; Surgery, Plastic